融信中國(03301.HK)附屬擬發行不超13.18億元公司債
格隆匯 2 月 2日丨融信中國(03301.HK)發佈公吿,融信(福建)投資集團有限公司(發行人,公司間接附屬公司)已向上海證券交易所遞交申請,申請向專業投資者公開發行本金總額不多於人民幣96.6億元(包括人民幣96.6億元)的境內公司債券。
2021年2月2日,上海證券交易所已批准發行人有關建議向專業投資者公開發行面值不超過人民幣13.18億元的第一期2021年境內公司債券的申請。第一期境內公司債券期限為五年期,附第二年末和第四年末發行人調整票面利率選擇權和投資者回售選擇權。是次發行的第一期境內公司債券將於上海證券交易所上市。發行人和主承銷商將於2月3日向專業投資者進行簿記建檔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.